Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyperus iria extract is derived from Cyperus iria Linn., an annual sedge weed also known as ricefield flatsedge or payong-payong. The extract, commonly prepared from roots or whole plant using ethanol or aqueous solvents, is rich in terpenoids (notably sesquiterpenoids such as β-elemene, E-β-caryophyllene, α-humulene, and α-farnesene), flavonoids, phenolic acids, and saponins. Studies indicate that cyperus iria extract exhibits notable anti-inflammatory and cytoprotective effects, including inhibition of protein denaturation and stabilizing red blood cell membranes, with activity comparable to standard anti-inflammatory drugs (e.g., celecoxib) in vitro and non-toxic at relevant concentrations. Additional research documents antifungal and allelopathic properties, affecting plant growth and photosynthesis in agricultural contexts. The full mechanism is not yet fully elucidated but may involve membrane stabilization and protein stabilization. Preliminary studies also suggest potential anti-diabetic and antioxidant effects. No specific pharmaceutical developer or product formulation is widely marketed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyperus iria extract.